These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 16460685)

  • 1. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
    Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
    Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-synuclein overexpression model.
    Mochizuki H; Yamada M; Mizuno Y
    J Neural Transm Suppl; 2006; (70):281-4. PubMed ID: 17017543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Neuroscience; 2012 Feb; 203():170-9. PubMed ID: 22198020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
    Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
    Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra.
    von Bohlen und Halbach O; Minichiello L; Unsicker K
    FASEB J; 2005 Oct; 19(12):1740-2. PubMed ID: 16037097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease.
    Mochizuki H; Hayakawa H; Migita M; Shibata M; Tanaka R; Suzuki A; Shimo-Nakanishi Y; Urabe T; Yamada M; Tamayose K; Shimada T; Miura M; Mizuno Y
    Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10918-23. PubMed ID: 11535810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
    Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
    Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
    Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-Synuclein multimer.
    Xu J; Wei C; Xu C; Bennett MC; Zhang G; Li F; Tao E
    Brain Res; 2007 Mar; 1139():220-5. PubMed ID: 17280646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi.
    Sapru MK; Yates JW; Hogan S; Jiang L; Halter J; Bohn MC
    Exp Neurol; 2006 Apr; 198(2):382-90. PubMed ID: 16455076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
    Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
    Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
    Decressac M; Mattsson B; Björklund A
    Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.